Which class of anti-cancer targeted drugs does Trametinib belong to?

Trametinib is an oral anti-cancer targeted drug that belongs to the MEK inhibitor class. It mainly blocks the abnormal proliferation and survival of tumor cells by inhibiting the MEK1 and MEK2 kinase activities in the intracellular RAS/RAF/MEK/ERK signaling pathway. This pathway is often activated due to gene mutations in a variety of tumors, especially in melanoma patients with positive BRAF gene mutations. Trametinib was designed to specifically target this pathway and is highly selective.

The drug was developed by GlaxoSmithKline (GSK) and was initially approved by the U.S.FDA in 2013 for the treatment of BRAF Patients with metastatic melanoma with V600E or V600K mutations. Unlike other targeted drugs, trametinib is often used in combination with BRAF inhibitors (such as davatinib, dabrafenib) to enhance the therapeutic effect and delay the occurrence of drug resistance. Studies have shown that the combination of the two can significantly extend the progression-free survival and overall survival of patients, and is one of the current standard regimens for the treatment of BRAF mutated melanoma.

In addition to melanoma, trametinib has also been studied for other solid tumors with abnormal RAS or BRAF pathways, such as lung cancer, thyroid cancer and colorectal cancer. It also shows some therapeutic potential in certain types of tumors with specific mutations. In recent years, with the development of precision cancer treatment, the application scope of trametinib is gradually expanding, but its indications are still mainly concentrated in the BRAF mutation-positive tumor population.

In general, trametinib is a typical MEK targeted inhibitor, mainly suitable for tumor types with activation of the MAPK pathway. Its target is clear and its effect is precise, and it plays an important role in the treatment of melanoma. During medication, you need to pay attention to possible side effects, such as rash, diarrhea, effects on heart function, etc. Therefore, it is recommended to conduct treatment and monitoring under the guidance of a professional doctor.

Reference materials:https://go.drugbank.com/drugs/DB08911